1935 ⎘
Rearing or breeding animals, not otherwise provided for; New breeds of animals; New breeds of vertebrates; Genetically modified vertebrates, e.g. transgenic Knockout animals
NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO
#902COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM CELL EXPANSION OR FOR MODULATING ANGIOGENESIS
#903Method of Treating Pain by Using Opioids and CAMKIV Inhibitors
#904MOUSE IN WHICH GENOME IS MODIFIED
#905IL-21 RECEPTOR KNOCKOUT ANIMAL AND METHODS OF USE THEREOF
#906COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASES
#907Method of deleting an IgM gene in an isolated rat cell
#908Inhibitors of PDE4 and Methods of Use
#909METHODS FOR RELIEVING NEUROPATHIC PAIN BY MODULATING ALPHA 1G T-TYPE CALCIUM CHANNELS AND MICE LACKING ALPHA 1G T-TYPE CALCIUM CHANNELS
#910SELECTIVE INHIBITION OF HISTONE DEACETYLASES 1 AND 2 AS A TREATMENT FOR CARDIAC HYPERTROPHY
#911Methods for producing transgenic rodents having recombinant immunoglobulin loci
#912REGENERATION AND SURVIVAL OF CARDIAC PROGENITORS AND CARDIOMYOCYTES WITH A STRETCH ACTIVATED TRANSCRIPTION FACTOR
#913Normal-tension glaucoma model and method for evaluation of test substances by using same
#914Lysyl oxidase-like 1 (LOXL1) and elastogenesis
#915Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
#916Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation
#917METHODS AND COMPOSITIONS FOR THE TREATMENT OF FIBROTIC CONDITIONS AND IMPAIRED LUNG FUNCTION AND TO ENHANCE LYMPHOCYTE PRODUCTION
#918Nonhuman model animal lacking the ability to control lymphocyte migration
#919Methods of using angiopoietin-like 4 protein to stimulate proliferation of pre-adipocytes
#920TARGETED GENE DISRUPTIONS IN THE IQGAP2 GENE
#921ANIMAL MODEL
#922METHOD AND COMPOSITIONS FOR MODULATING TH17 CELL DEVELOPMENT
#923Novel therapeutic and diagnostic products and methods
#924Methods for increasing the diversity of monoclonal antibodies produced against an antigen
#925Use of Tumor Necrosis Factor-Alpha P75 Receptor for the Reduction of Inflammation
#926TRANSGENIC ANIMAL MODEL FOR MODELLING PATHOLOGICAL ANXIETY, A METHOD FOR IDENTIFYING COMPOUNDS FOR TREATMENT OF DISEASES OR DISORDERS CAUSED BY PATHOLOGICAL ANXIETY AND A METHOD FOR USING WFS1 PROTEIN AS A TARGET FOR IDENTIFYING EFFECTIVE COMPOUNDS AGAINST PATHOLOGICAL ANXIETY
#927TRANSGENIC NON-HUMAN ANIMAL
#928Reduction of graft-versus-host disease by modulation of SHIP activity
#929Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor
#930Transgenic chickens with an inactivated endogenous gene locus
#931IDENTIFICATION OF GROUP OF HYPERTENSION-SUSCEPTIBILITY GENES
#932MAVS IN THE PREVENTION AND TREATMENT OF VIRAL DISEASE
#933Use of FGF-18 Protein, Target Proteins and Their Respective Encoding Nucleotide Sequences to Induce Cartilage Formation
#934ANIMAL MODEL FOR THE SELECTION AND VALIDATION OF AGENTS ACTIVE AGAINST PULMONARY EMPHYSEMA AND COLORECTAL CANCER
#935Artery- and vein-specific proteins and uses therefor
#936Osteopontin Specific Antibodies and Methods of Use Thereof
#937METHODS FOR DETECTING AND TREATING KIDNEY DISEASE
#938Models of thrombotic thrombocytopenic purpura and methods of use thereof
#939Animal model and use of 17beta-hydroxysteroid dehydrogenase type 7 in the diagnosis of anencephaly
#940C-REACTIVE PROTEIN (CRP) KNOCKOUT MOUSE
#941Method for preventing and treating cardiovascular diseases with BRCA1
#942CRANIAL AND VERTEBRAL DEFECTS ASSOCIATED WITH LOSS-OF-FUNCTION OF NELL1
#943Regulation of lipid droplet formation by modulation of FIT1 and FIT2 and uses thereof
#944METHODS AND REAGENTS FOR SCREENING NEW DRUGS AND FOR TREATING ION PUMP ASSOCIATED DISORDERS AND DISEASES
#945SCREENING METHOD WITH THE USE OF TBK1 KNOCKOUT MOUSE
#946Treatment of Pompe's Disease
#947Ungulates with genetically modified immune systems
#948GENES AND PATHWAYS INVOLVED IN BIPOLAR DISORDER
#949METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
#950Animal having modification in MGAT2 gene
#951Transgenic non-human animals expressing a truncated activin type II receptor
#952Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
#953PROTEIN FORMULATIONS COMPRISING S1-5
#954Cardiac hypertrophy
#955Application of actin-binding protein to disease associated with cell motility
#956KNOCKOUT ANIMAL EXHIBITING ANXIETY-LIKE BEHAVIOR
#957Ferroportin1 nucleic acids, proteins, antibodies and methods
#958Human CTLA-4 antibodies and their uses
#959Use of VEGF and homologues to treat neuron disorders
#960METHODS FOR MANIPULATING STEM CELLS
#961Mouse model for eye disease
#962Novel gene disruptions, compositions and methods relating thereto
#963Prion-free transgenic ungulates
#964Prostate Epithelial Androgen Receptor Suppresses Prostate Growth and Tumor Invasion
#965Negative regulation of NK cell functions by EAT-2, a sap-related adaptor expressed in innate immune cells
#966METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE MEMORY BY BLOCKING INTRAHEPATIC ACTIVATED T CELL DELETION
#967Saspase knockout animal
#968MG53 compositions and methods of use
#969Tl1a in treatment of disease
#970Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity
#971Gene disruptions, compositions and methods relating thereto
#972Nucleic acid sequences and homologous recombination vectors for distruption of a Fel D I gene
#973Use of Caspase-8 Inhibitors for Modulating Hematopoiesis
#974Novel Gene Disruptions, Compositions and Methods Relating Thereto
#975Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
#976SGRF gene-modified mouse
#977Novel Gene Disruptions, Compositions and Methods Relating Thereto
#978Production of ungulates, preferably bovines that produce human immunoglobulins
#979TRANSGENIC ANIMALS WITH REDUCED MAJOR URINARY PROTEIN PRODUCTION
#980Protein formulations comprising s1-5
#981SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY
#982Growth differentiation factor-11
#983Transgenic non-human animals for producing chimeric antibodies
#984Isolated human chromosome 14 fragment encoding immunoglobulin genes
#985CISD2-Knockout Mice and Uses Thereof
#986Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
#987Transgenic non-human animals for pharmacological and toxicological studies
#988Non-human mammal comprising a modified SERCA2 gene and methods, cells, genes, and vectors thereof
#989Methods and compositions for using sax2
#990Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes
#991Transgenic pig with altered incretin function
#992Methods of studying tolerance in MHC-II transgenic animals
#993Method of producing xenogenous antibodies using a bovine
#994GENES
#995Identification of TRPML3 (MCOLN3) as a salty taste receptor and use in assays for identifying taste (salty) modulators and/or therapeutics that modulate sodium transport, absorption or excretion and/or aldosterone, and/or vasopressin production or release
#996Anti-Neovasculature Preparations for Cancer
#997Caspase-9 deficient animals and the use thereof
#998Genetically modified non-human mammals and cells
#999Genomic editing in zebrafish using zinc finger nucleases
#1000Compositions and methods for treating gram positive bacterial infection in a mammalian subject
#1001MODEL ANIMAL OF DENDRITIC CELL IMMUNORECEPTOR GENE KNOCKOUT DISEASE
#1002Gene disruptions, compositions and methods relating thereto
#1003Genetically Engineered and Phenotyped Mice and Stem Cell Clones for Producing the Same
#1004Truncated Activin Type II Receptor and Methods of Use
#1005Diagnosis of fertility conditions using a serine protease
#1006Mouse carrying a knock-out mutation of the Qpct-gene
#1007Novel apolipoprotein gene involved in lipid metabolism
#1008Transgenic Zebrafish Models for Neurodegenerative Diseases
#1009Identification of a micro-RNA that activates expression of β-myosin heavy chain
#1010Treatment of Conditions Involving Demyelination
#1011Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof
#1012COMPOSITIONS AND METHODS OF MAKING EMBRYONIC STEM CELLS
#1013TREATMENT OF EPILEPSY BY EXPRESSING ST3GAL-III
#1014Expression Vectors Comprising the HS1 Promoter of the VAV1 Oncogene and Use Thereof for the Preparation of Pharmaceutical Compositions Intended for Somatic Gene Therapy
#1015Transgenic bovine having reduced prion protein activity and uses thereof
#1016Noxin, a novel stress-induced gene involved in cell cycle and apoptosis
#1017Nucleic acid molecules encoding indoleamine 2,3-dioxygenase-2
#1018DNA encoding polypeptide capable of modulating muscle-specific tyrosine kinase activity
#1019TLR ligand and IL-1 Response-Injured Animal Model
#1020Glycine N-methyltransferase (GNMT) Animal model and use thereof
#1021Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
#1022Novel Gene Disruptions, Compositions and Methods Relating Thereto
#1023METHODS FOR TREATING A DISORDER BY REGULATING GPRC6A
#1024HBM variants that modulate bone mass and lipid levels
#1025Mice lacking alpha 1G showing enhanced novelty-seeking and alcohol preference and therapeutic methods for mood disorders by modulating alpha 1G T-type calcium channels
#1026Compositions and methods for regulating apoptosis
#1027Muscle lamin A/C interacting protein, gene encoding same, and uses therefor
#1028Germ cells having inactivated endogenous immunoglobulin genes, and transgenic animals derived therefrom
#1029Mouse in Which Genome is Modified
#1030Vitamin K Epoxide Recycling Polypeptide VKORC1, a Therapeutic Target of Coumarin and Their Derivatives
#1031Neuromedin u receptor subtype 1 deficient transgenic mice and uses thereof
#1032Model animal causing the white hair development and methods relating thereto
#1033CYR61 COMPOSITIONS AND METHODS
#1034Cardiac progenitor cells
#1035Model of Alzheimer's Disease
#1036Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same
#1037MAMMALIAN GRAINYHEAD TRANSCRIPTION FACTORS
#1038Methods for addressing ocular diseases through interference with the wnt signaling pathway
#1039PNMT as a novel marker for progenitor cells
#1040Vldlr-/- mouse models and related methods
#1041Transgenic or recombinant non-human mammals and their uses in screening psychoactive medicines
#1042Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
#1043PORCINE CMP-N-ACETYLNEURAMINIC ACID HYDROXYLASE GENE
#1044GPR 26 G-Protein Coupled Receptor
#1045Inhibitors of prolyl-hydroxylase-1 for the treatment of skeletal muscle degeneration
#1046Osteopontin Specific Antibodies and Methods of Use Thereof
#1047CAP/SORBS1 AND DIABETES
#1048Glycine N-methyltransferase (GNMT) animal model and use thereof
#1049METHODS AND COMPOSITIONS FOR THE TREATMENT OF FIBROTIC CONDITIONS & IMPAIRED LUNG FUNCTION & TO ENHANCE LYMPHOCYTE PRODUCTION
#1050TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6
#1051Lysyl oxidase-like 1 (LOXL1) and elastogenesis
#1052Oasis gene-deficient mouse
#1053Chicken growth differentiation factor-8
#1054Compositions and methods for altering bone density and bone patterning
#1055Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
#1056TREATMENT OF CANCER WITH ANTI-MUSCARINIC RECEPTOR AGENTS
#1057Method for modifying chromosomes
#10587B2 Knockout transgenic animals as models of endocrine disease
#1059Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
#1060Methods for Detection of Mutations in Myostatin Variants
#1061Novel Gene Disruptions, Compositions and Methods Relating Thereto
#1062BISPECIFIC ANTIBODIES
#1063TRANSGENIC TIEG NON-HUMAN ANIMALS
#1064ECAT16 gene expressed specifically in ES cells and utilization of the same
#1065Methods for treating vascular disease
#1066Screening method for somatic cell nuclear reprogramming substance affecting ECAT2 and ECAT3
#1067Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation
#1068Ant2 Conditional Knockout Mouse and Methods
#1069Neuregulin-1 transgenic mouse and methods of use
#1070Methods for identifying modulators of protein kinase C-epsilon (PKC) and method of treatment of aberrant glucose metabolism associated therewith
#1071Animal Model for Studying Atherosclerotic Lesions
#1072Regulation of mink in thymocytes and T lymphocytes
#1073Animal models of pancreatic adenocarcinoma and uses therefor
#1074Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
#1075ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY
#1076Transgenic mammal carrying GANP gene transferred thereinto and utilization thereof
#1077sFRP expression enhancing agent
#1078Dampening Humoral and Innate Immunity by Inhibition of Ppgalnact-1
#1079Polypeptide, novel DNA and novel antibody
#1080Vectors having both isoforms of beta-hexosaminidase and uses of the same
#1081Transgenic non-human animal for use in research models for studying Parkinson's disease
#1082Animal model for cancer, methods of producing the same and associated methods of use
#1083Growth Differentiation Factor-8
#1084Compositions and methods for modulating S-nitrosoglutathione reductase
#1085Treatment of Pompe's disease
#1086Mouse in which genome is modified
#1087Transgenic mouse whose genome comprises a homozygous disruption of its α1G gene, a method of preparing the same and use thereof
#1088GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF
#1089COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS
#1090Use of Fgf-18 Protein, Target Proteins and Their Respective Encoding Nucleotide Sequences to Induce Cartilage Formation
#1091Genetically engineered and phenotyped mice and stem cell clones for producing the same
#1092Screening Method With The Use Of TBK1 Knockout Mouse
#1093DISEASE MODEL ANIMALS OF METABOLIC SYNDROME AND A METHOD OF SCREENING PREVENTIVE AND THERAPEUTIC AGENTS FOR METABOLIC SYNDROME USING THE SAME
#1094Growth Differentiation Factor-8 Nucleic Acid and Polypeptide from Aquatic Species, and Transgenic Aquatic Species
#1095Neuromedin u receptor subtype 1 deficient transgenic mice and uses thereof
#1096METHODS OF INDUCING AND TREATING VASCULAR DISEASE
#1097Nonhuman model animal lacking the ability to control lymphocyte migration
#1098Methods and Compositions for Using Tsh in the Inhibition of Tnf Activity
#1099Culturing human cells and tissues in an N-glycolylneuraminic acid-free environment
#1100IL-21 AS A REGULATOR OF IMMUNOGLOBIN PRODUCTION
#1101Nonhuman model animal lacking the ability to control lymphocyte migration
#1102Gene disruptions, compositions and methods relating thereto
#1103Compositions and methods for treatment of autoimmune and related diseases
#1104Transgenic animals for assessing drug metabolism and toxicity
#1105Methods for Inhibiting Melanocyte Stem Cell Loss
#1106Compositions and methods for modulation of KSR1 and KSR2 interactions
#1107Transgenic Animal Models for Neurodevelopmental Disorders
#1108Method for treatment and prevention of ultraviolet light induced skin pathologies
#1109Methods and means for increasing resistance to cell damage
#1110Drugs For Diseases Accompanying Changes In Total Bile Acid Pool Or Lipid Metabolism Disorders And Method Of Screening These Drugs
#1111SAPAP3 knockout mouse and clinical modeling associated with the SAPAP3 gene
#1112DISEASE MODEL ANIMALS OF METABOLIC SYNDROME AND A METHOD OF SCREENING PREVENTIVE AND THERAPEUTIC AGENTS FOR METABOLIC SYNDROME USING THE SAME
#1113CISD2-Knockout Mice and Uses Thereof
#1114Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
#1115Methods of modulating apoptosis by administration of relaxin agonists or antagonists
#1116Method for making homozygous genetic modifications
#1117Conditioned culture media
#1118Control of NK cell function and survival by modulation of SHIP activity
#1119Control Of Diabetes And Obesity
#1120Mouse model of chronic heart failure and coronary atherosclerosis regression
#1121Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
#1122Regulation of oncogenesis by Akt-specific isoforms
#1123Phospholipase C β1 (PLCβ1) knockout mice as a model system for testing schizophrenia drugs
#1124Modified Cells and Methods of Using Same
#1125Prevention of primary sjogren' s Syndrome by ICA69 deficiency
#1126METHODS AND COMPOSITIONS FOR TARGETING RELT
#1127Mouse model of cholinergic dysfunction to evaluate cognitive enhancers and drugs that improve myasthenia
#1128TRPS1-mediated modulation of hair growth
#1129Transgenic mice for screening for inhibitors of protein aggregation and methods for making and using them
#1130Grp Receptor-Related Methods for the Treating and Preventing Fear-Related Disorders
#1131Nonhuman model animal of Th2-mediated hyperimmune response
#1132Retinal dystrophin transgene and methods of use thereof
#1133Method of Suppressing Cancer
#1134Methods for detecting and treating kidney disease
#1135Animal model of neurodegenerative diseases, the procedure for producing the model and applications thereof
#1136Fluid flow meter body with high immunity to inlet/outlet flow disturbances
#1137Knockout Non-Human Animal
#1138Use of VEGF and homologuest to treat neuron disorders
#1139Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene
#1140Method of proliferation in neurogenic regions
#1141Method for making genetic modifications
#1142Ungulates with genetically modified immune systems
#1143Uses of Sperm Membrane Protein Obf
#1144Permeability of blood-brain barrier
#1145MICE LACKING ALPHA 1G SHOWING ENHANCED NOVELTY-SEEKING AND ALCOHOL PREFERENCE AND THERAPEUTIC METHODS FOR MOOD DISORDERS BY MODULATING ALPHA 1G T-TYPE CALCIUM CHANNELS
#1146Transgenic mice carrying functional single nucleotide polymorphisms in brain-specific tryptophan hydroxylase
#1147Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of SOCS sequence in the animal
#1148Methods for Relieving Neuropathic Pain by Modulating Alpha1G T-Type Calcium Channels and Mice Lacking Alpha 1G T-Type Calcium Channels
#1149MAVS in the prevention and treatment of viral diseases
#1150Methods for Identifying Treatment and Inducing Infertility Using Smc1-Beta
#1151Chimeric cancer models
#1152PRO224 gene disruptions, and methods related thereto
#1153Method for testing a compound for a therapeutic effect and a diagnostic method
#1154Ornithine aminotransferase (OAT): a target for anticancer drugs
#1155Methods of Validating Target for Modulating Insulin Action, Screening for Modulators of Insulin Action and Therapeutic Uses Thereof
#1156Animal Selected For Lacking Heparan Sulfate-3-O-Sulfotransferase-1 and Uses Thereof
#1157Methods of Identifying Compounds Which Modulate Granulocite-Colony Stimulating Factor (G-Csf) Dependent Processes by Modulation of the Levels of Suppressor of Cytokine Signaling (Socs)
#1158Use of Caspase-8 Inhibitors for Modulating Hematopoiesis
#1159KSR2 knockout mice and methods of use thereof
#1160Regulation of glucose and insulin levels by GnT-4 glycosyltransferase activity
#1161Methods and compositions for recovering or improving visual function
#1162VEGF Receptor Conditional Knockout Animals and Methods of Use
#1163Mannose binding lectin knock-out mice and methods of use thereof
#1164Modulation of immune response and inflammation by targeting hypoxia inducible factors
#1165Use of VEGF and homologues to treat neuron disorders
#1166Use of the receptor GPR86
#1167Method for preventing or treating neuropathic pain
#1168O-GLYCANS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND CANCERS
#1169Methods for use of TSLP and agonists and antagonists thereof
#1170GDF-9/BMP-15 modulators for the treatment of bone disorders
#1171Human G protein-coupled receptor and modulators thereof for the treatment of cardiovascular disorders
#1172Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
#1173Ferroportin1 antibodies and methods
#1174Transgenic animals and methods of monitoring hedgehog responding cells
#1175Muscle regeneration compositions and uses therefor
#1176Diabetes treatment methods and drug targets therefor
#1177Methods and compositions for modulating the mobilization of stem cells
#1178Knockout mouse for the tumor suppressor gene ANX7
#1179Transgenic mice containing TRP gene disruptions
#1180Methods for treating conditions associated with MASP-2 dependent complement activation
#1181Methods and compositions for modulating gamete adhesion
#1182Ion channel
#1183Methods and compositions for treating motor neuron associated disorders
#1184BLOCKING LEUKOCYTE EMIGRATION AND INFLAMMATION BY INTERFERING WITH CD99/HEC2
#1185SPC7 Serine Protease Gene Disruptions, Compositions and Methods Related Thereto
#1186Mutation in the rat adenomatous polyposis coli gene within the human mutation hotspot region
#1187Methods and compositions for inhibition of immune responses
#1188Compositions and methods for modulating the acute phase response
#1189Method for preventing and treating diabetes using dg119
#1190Method of modulating fertility in animals
#1191Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
#1192Disruptions in GABA Receptor RHO2 Subunit, Methods and Uses Thereof
#1193Methods for controlling pathological angiogenesis by inhibition of a6b4 integrin
#1194Antibodies against epitopes with homology to self antigens, methods of preparation
#1195Transgenic mice carrying the HP-2 gene and uses as models for vascular diseases
#1196Ion channel
#1197Transgenic non-human animals for pharmacological and toxicological studies
#1198Methods and means for inhibiting fever
#1199Method for screening PTPzeta activity promoter or inhibitor
#1200Transgenic Mice Containing GPCR5-1 Gene Disruptions